Replay available

Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Q4 2025 earnings conference call, held 2026-03-09. Replay captured from the company's public earnings webcast.

Mon, March 9, 2026 at 4:30 PMendedReplay
Zevra Therapeutics, Inc.  (ZVRA) Q4 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Nicole Oshner

Vice President of Investor Relations and Corporate Communications

Neal McFarlane

President and Chief Executive Officer

Josh Schaefer

Chief Commercial Officer

Justin Renz

Chief Financial Officer

Kristen Kluska

Analyst, Cantor Fitzgerald

Jason Butler

Analyst, Citizens

Eddie Hickman

Analyst, Guggenheim Securities

Sumant Kulkarni

Analyst, Canaccord Genuity

Brandon Foulkes

Analyst, HC Wainwright

Lachlan Hanbury-Brown

Analyst, William Blair

Replay transcript excerpt

Good afternoon, and thank you for joining Debra's fourth quarter and full year 2025 financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the company's website later today. The host for today's call is Nicole Oshner, Debra's vice president of investor relations and corporate communications. Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of our fourth quarter and full year 2025 financial results. I encourage you to read the financial results news release, which was distributed this afternoon and is available in the investors section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with Debra's business. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties, and other important factors that may lead to actual results differing materially from the projections made. and should be evaluated together with the risk factor section in our most recent quarterly report on Form 10Q, our annual report on Form 10K, and other filings with the SEC. I'm pleased to welcome ZEVRA's management team members participating in today's call. Neal McFarlane, ZEVRA's President and Chief Executive Officer, and Josh Schaefer, our Chief Commercial Officer, Our Chief Medical Officer, Adrian Cortell, and our Senior Vice President of Finance and Corporate Controller, Timothy Sangiovanni, will be available for today's question and answer session. ...

More from Zevra Therapeutics, Inc.